Some on Wall Street appear to be concerned about a potential private credit crisis. Worrisome signs can be found in a few ultra-high-yield BDC stocks. However, one BDC stock appears to be in a good ...

Investing.com -- Standard Chartered has lowered its near-term price forecasts for digital assets, warning of further downside before a recovery later this year. Geoff Kendrick, StanChart’s global head ...

, Feb. 3, 2026 /PRNewswire/ -- New analysis shows publicly listed business development companies lagging non-traded BDC peers across key risk metrics Heron Finance released a Monthly Insights report, ...

Scion Asset Management founder Michael Burry, the hedge fund manager who rose to fame predicting the 2008 housing crisis, has shared a Bitcoin chart on X comparing the current pullback to the 2021–22 ...

Business Development Companies (BDCs) face mounting risk from AI-driven disruption in software and technology sector loan portfolios. Peak-valuation software loans, especially those originated in 2021 ...

The bitcoin price crash has stoked fears of another "crypto winter" and has shaken faith in a trade that many thought would rival gold as a store of value and remain bullish during a crypto-friendly ...

A BDC is a publicly regulated investment vehicle that helps small and mid-sized U.S. businesses get money when they cannot borrow from banks. BDCs collect money from investors and arrange it primarily ...

Bitcoin rebounds after testing an intraday low at $60,000 amid persistent retail investor exit. Ethereum shows subtle signs of recovery, but ETFs outflows limit upside. XRP gains by over 10% on Friday ...

How and Why to Invest in ETFs: Demystifying the Vehicle Taking Markets by Storm Natural gas futures plunged 8.3% on Monday as traders priced in the end of winter demand and a shift toward lower ...

Bitcoin consolidates above $77,000 after plummeting and testing April’s tariff-triggered lows, as investors remain cautious. Ethereum extends losses toward the psychological $2,000 support amid ETF ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...